Skip to navigation Skip to content

ASSESS MS Study: FTY720D2312

Share

Details

MS Center Innovations in Care, Missouri Baptist Medical Center
3009 North Ballas
Building B, Suite 207B
St. Louis, MO 63131
See Map

Summary
A 12-month, randomized, rater-and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.
 
Participant Criteria
Click here for more information
 
Contact
Delea Payne-Gates, CCRP
314-996-7775

Share


Chapter HomeReturn to list
© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.